Efficacy and Safety of Vorapaxar in Non–ST‐Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery

Efficacy and Safety of Vorapaxar in Non–ST‐Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery

Background Perioperative antiplatelet agents potentially increase bleeding after non–ST‐segment elevation (NSTE) acute coronary syndromes (ACS). The protease‐activated receptor 1 antagonist vorapaxar reduced cardiovascular events and was associated with increased bleeding versus placebo in NSTE ACS,...

Full description

Bibliographic Details
Main Authors: Sean vanDiepen, Pierluigi Tricoci, Mohua Podder, Cynthia M. Westerhout, Philip E. Aylward, Claes Held, Frans Van de Werf, John Strony, Lars Wallentin, David J. Moliterno, Harvey D. White, Kenneth W. Mahaffey, Robert A. Harrington, Paul W. Armstrong
Format: Article
Language:English
Published: Wiley 2015-12-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
coronary disease
hemorrhage
noncardiac surgery
non–ST‐segment elevation acute coronary syndromes
surgery
vorapaxar
Online Access:https://doi.org/10.1161/JAHA.115.002546

Internet

https://doi.org/10.1161/JAHA.115.002546

Similar Items